SCHEDULE: State Street Discloses 5.3% Stake in REGENXBIO

State Street Corporation has reported beneficial ownership of 5.3% of REGENXBIO Inc.'s common stock as of March 31, 2026.

Summary

• State Street Corporation has filed a Schedule 13G, indicating it beneficially owns 2,731,553 shares of REGENXBIO Inc. common stock.
• This ownership represents 5.3% of the total class of securities.
• The filing date is March 31, 2026, and State Street Corporation is classified as a holding company.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While a significant institutional holding can be positive, the Schedule 13G is a routine disclosure of passive ownership and does not provide insights into the company's performance or future prospects.

Positives

• State Street Corporation's investment indicates confidence in REGENXBIO Inc.'s long-term prospects.
• A significant institutional investor holding a substantial stake can provide stability and market credibility.

Negatives

• The filing does not provide specific details on the acquisition cost or the exact strategy behind the investment, limiting deeper analysis of its immediate financial impact.

Risks

• Potential for future changes in State Street Corporation's holdings, which could impact REGENXBIO's stock price.
• The filing does not detail specific risks associated with REGENXBIO Inc.'s business operations, focusing solely on ownership.

Future Outlook

The filing does not contain forward-looking statements or guidance from REGENXBIO Inc. It solely reports on State Street Corporation's ownership stake.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."
• "STATE STREET CORPORATION Signature: ELIZABETH SCHAEFER Name/Title: SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER"

Industry Context

StockSavvy.ai notes that significant institutional holdings, as reported in Schedule 13G filings, are common in the biotechnology sector, reflecting investor interest in companies with potentially high growth but also high risk profiles. REGENXBIO operates in the gene therapy space, an area attracting substantial investment.

Comparison to Industry Standards

• Institutional ownership of 5.3% by a single entity like State Street Corporation is a notable stake, often considered significant for a company of REGENXBIO's size and stage.
• Many biotechnology companies, especially those in clinical development, see substantial ownership by investment firms and asset managers, with stakes often ranging from 5% to over 20% for major holders.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's passive stake, which may be viewed positively for stability, but offers no direct performance indicators.
• Management: The filing is a routine disclosure and does not directly impact management's operational decisions, but signals continued institutional interest.

Next Steps

• Monitor future filings from State Street Corporation for any changes in their beneficial ownership of REGENXBIO Inc. stock.
• Observe REGENXBIO Inc.'s operational and clinical developments for potential impact on institutional investor sentiment.

Key Dates

Keywords

REGENXBIO, State Street Corporation, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology, Gene Therapy